Study of a Polymorphism in Patients With Prostate Cancer
|ClinicalTrials.gov Identifier: NCT00900185|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : April 30, 2015
RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA.
PURPOSE: This laboratory study is looking at blood samples from patients with prostate cancer and from healthy participants to identify a polymorphism that may help in the study of prostate cancer.
|Condition or disease||Intervention/treatment|
|Prostate Cancer||Genetic: mutation analysis Genetic: polymerase chain reaction Genetic: polymorphism analysis|
- Determine the incidence of the D104N COL18A1 polymorphism in patients with prostate cancer.
- Determine the incidence of this polymorphism in African-American patients with prostate cancer.
OUTLINE: This is a retrospective, multicenter study.
DNA is extracted from preexisting serum samples and polymerase chain reaction is performed to determine the genotype pattern.
PROJECTED ACCRUAL: A total of 500 patients and 250 healthy participants will be accrued for this study.
|Study Type :||Observational|
|Estimated Enrollment :||750 participants|
|Official Title:||Retrospective Analysis of Endostatin Genotype in Prostate Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (D104N) in Endostatin and Prostate Cancer|
- Frequency of D104N COL18A1 polymorphism in patients with prostate cancer and in healthy participants
- Frequency of D104N COL18A1 polymorphism in African-American patients with prostate cancer and in healthy participants
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900185
|Study Chair:||William D. Figg, PharmD||National Cancer Institute (NCI)|